A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

NCT07016997 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Refractory Cancer

Interventions

DRUG: CBA-1535
DRUG: CBA-1535+Pembrolizumab

Sponsor

Chiome Bioscience Inc.